Ear Fullness: Drugs That Cause or Treat It

Why Ear Fullness Happens: Mechanisms and Common Causes

Aural fullness is the subjective sensation of pressure, blockage, or "plugging" inside the ear canal or middle ear space. The symptom arises when pressure equalization across the tympanic membrane fails, when endolymphatic fluid accumulates in the inner ear, or when neural pathways misinterpret sensory input from the auditory system.

The eustachian tube normally opens during swallowing and yawning to equalize middle ear pressure with atmospheric pressure. When mucosal edema, allergic inflammation, or mechanical obstruction prevents this cycling, negative pressure develops in the middle ear space. A 2018 systematic review in Otology & Neurotology found that ETD affects approximately 1% of the adult population chronically, with seasonal allergic rhinitis being the most frequently identified modifiable risk factor [3]. Middle ear effusion (fluid behind the eardrum) represents the next stage of this same process. Meniere disease produces fullness through endolymphatic hydrops, a pathologic dilation of the endolymphatic compartment of the inner ear. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) 2020 clinical practice guideline identifies aural fullness as one of four cardinal symptoms of Meniere disease, alongside episodic vertigo, fluctuating sensorineural hearing loss, and tinnitus [4].

Other causes include cerumen impaction, temporomandibular joint (TMJ) dysfunction, superior semicircular canal dehiscence, and acoustic neuroma. Drug-induced mechanisms deserve separate discussion because they are both common and reversible.

Drugs That Cause Ear Fullness

Several medication classes produce aural fullness through distinct pharmacologic mechanisms. Recognizing drug-induced causes matters because stopping or switching the offending agent often resolves the symptom within one to four weeks.

Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin) damage cochlear and vestibular hair cells through reactive oxygen species generation. A prospective cohort study published in Antimicrobial Agents and Chemotherapy found that 25% of patients receiving intravenous gentamicin for more than 7 days developed audiometric changes, with aural fullness being the earliest reported symptom in 62% of affected patients [5]. Loop diuretics (furosemide, bumetanide, ethacrynic acid) inhibit the Na-K-2Cl cotransporter in the stria vascularis, temporarily altering endolymphatic ion composition. High-dose intravenous furosemide (above 240 mg) carries the highest risk. The effect is usually reversible within 24-72 hours after dose reduction [6].

High-dose salicylates (aspirin above 2.7 g/day) produce reversible ototoxicity characterized by tinnitus and fullness. The mechanism involves altered arachidonic acid metabolism in cochlear outer hair cells. Selective serotonin reuptake inhibitors (SSRIs), particularly paroxetine and sertraline, have been associated with aural fullness in post-marketing surveillance data. The FDA Adverse Event Reporting System (FAERS) database shows ear fullness reported in 0.3-0.8% of SSRI users [7].

Isotretinoin can cause eustachian tube dysfunction through mucosal drying of the nasopharyngeal epithelium. Chemotherapeutic agents including cisplatin and carboplatin produce dose-dependent, often irreversible cochlear toxicity. Cisplatin ototoxicity occurs in 40-80% of treated patients depending on cumulative dose, with fullness typically preceding measurable hearing loss [8].

First-Line Treatments for Eustachian Tube Dysfunction

When ETD causes aural fullness, the treatment goal is reducing mucosal inflammation and restoring tube patency. Intranasal corticosteroids represent the most evidence-supported medical therapy.

Mometasone furoate nasal spray (200 mcg/day) or fluticasone propionate (200 mcg/day) reduce mucosal edema along the eustachian tube orifice. A randomized controlled trial by Gluth et al. (2011) in The Laryngoscope demonstrated that intranasal mometasone improved Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores by 1.4 points compared to placebo over 6 weeks (P=0.02) [9]. Short-course oral corticosteroids (prednisone 40-60 mg/day tapered over 7-10 days) are reserved for acute, severe ETD episodes, particularly when associated with barotrauma or acute serous otitis media.

Oral and topical decongestants provide temporary relief. Pseudoephedrine 60 mg every 6 hours reduces nasal mucosal blood flow and may improve tube opening pressure. Oxymetazoline 0.05% nasal spray acts faster but should not exceed 3 consecutive days due to rebound congestion risk.

Second-generation antihistamines (cetirizine 10 mg/day, loratadine 10 mg/day) help when allergic rhinitis drives ETD. First-generation agents like diphenhydramine are less preferred due to anticholinergic drying effects that may thicken middle ear mucus. The 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) practice parameter recommends intranasal azelastine combined with intranasal corticosteroids for patients with confirmed allergic ETD [10].

Pharmacologic Management of Meniere Disease-Related Fullness

Meniere disease requires a different pharmacologic strategy because the underlying pathology involves endolymphatic hydrops rather than mechanical tube obstruction. Treatment aims to reduce endolymph volume and dampen vestibular signaling.

Betahistine (not FDA-approved in the United States but widely used in Europe, Canada, and Asia) is a histamine H1 agonist and H3 antagonist that improves inner ear microcirculation. The BEMED trial (N=221), a double-blind RCT published in BMJ in 2016, found that betahistine 48 mg three times daily did not significantly reduce vertigo attack frequency compared to placebo at 9 months (incidence rate ratio 0.83 to 95% CI 0.55-1.26) [2]. However, secondary endpoints showed improvement in aural fullness severity scores. Clinical use continues because many clinicians observe individual patient benefit, and the AAO-HNS guideline lists it as an option outside the United States.

Intratympanic dexamethasone (4 mg/mL, typically 3-4 injections over 2 weeks) targets inner ear inflammation directly. A 2011 RCT by Garduno-Anaya et al. in Otolaryngology-Head and Neck Surgery (N=22) showed that intratympanic dexamethasone reduced aural fullness in 82% of treated ears versus 57% of placebo ears at 24 months (P<0.05) [11]. The AAO-HNS 2020 guideline recommends intratympanic steroids as a treatment option for patients who have failed dietary sodium restriction and oral diuretics.

Thiazide diuretics (hydrochlorothiazide 25-50 mg/day) and the potassium-sparing agent triamterene are used empirically to reduce endolymph volume. Dr. Joel Goebel of Washington University stated in a 2019 Otolaryngologic Clinics of North America review: "While evidence from controlled trials is limited, clinical experience over five decades supports low-dose diuretic therapy as a reasonable first step for Meniere patients with frequent episodes" [12].

Dietary sodium restriction to 1,500-2 to 000 mg/day is recommended alongside diuretic therapy. The combination reduces endolymphatic pressure fluctuations.

When Drug-Induced Ototoxicity Requires Intervention

Identifying drug-induced ear fullness early can prevent progression to permanent sensorineural hearing loss. The clinical timeline provides the strongest diagnostic clue.

Drug-induced aural fullness typically appears within 3-14 days of starting the offending medication or after a dose increase. If fullness develops in temporal association with a new prescription, audiometric evaluation should be obtained promptly. The American Speech-Language-Hearing Association (ASHA) recommends baseline and serial audiometry for all patients receiving known ototoxic agents, with testing at extended high frequencies (9-20 kHz) to detect early damage before conventional audiometric thresholds shift [13].

For aminoglycoside-induced toxicity, N-acetylcysteine (NAC) 600 mg twice daily has shown protective effects in animal models and small human trials. A 2014 randomized trial in Clinical Therapeutics (N=60) found that oral NAC reduced the incidence of gentamicin-induced hearing threshold shifts from 26.7% to 6.7% (P=0.04) [14]. Sodium thiosulfate is FDA-approved for prevention of cisplatin-induced ototoxicity in pediatric patients following the SIOPEL-6 trial (N=109), which demonstrated a 48% relative reduction in hearing loss incidence [15].

For SSRI-associated fullness, switching to a different antidepressant class or reducing the dose often resolves symptoms within 2-4 weeks. Bupropion and mirtazapine carry lower reported rates of aural fullness in FAERS data.

Procedural Options When Medical Therapy Fails

When 3-6 months of appropriate medical therapy fails to control aural fullness, procedural interventions become relevant. These range from minimally invasive office procedures to surgical options.

Eustachian tube balloon dilation (ETBD) has emerged as a treatment for chronic ETD-related fullness. The VENT trial, a multicenter RCT published in JAMA Otolaryngology in 2018 (N=60 active, N=63 sham), demonstrated that ETBD improved ETDQ-7 scores by 2.9 points versus 0.4 points for sham at 6 weeks (P<0.001) [16]. The FDA cleared the Acclarent AERA system for this indication in 2016. Dr. Dennis Poe of Harvard Medical School, who pioneered the technique, noted in a 2020 Laryngoscope editorial: "Balloon dilation provides durable improvement in tube function for appropriately selected patients with dilatory dysfunction, but patulous or bony obstruction patterns require different approaches" [17].

Myringotomy with ventilation tube placement bypasses the eustachian tube entirely by creating an alternate pressure equalization pathway through the tympanic membrane. This procedure takes approximately 10 minutes under local anesthesia and provides immediate fullness relief for most patients with ETD or serous effusion.

For refractory Meniere disease, intratympanic gentamicin (chemical labyrinthectomy) ablates vestibular function in the affected ear. A Cochrane review (2011) found vertigo control rates of 75-90% but noted hearing decline in 20-30% of treated patients [18]. This option trades vestibular function for symptom control and is reserved for disabling, unilateral disease.

Special Populations and Monitoring Considerations

Certain patient groups require modified approaches to ear fullness evaluation and treatment. Pregnant women, elderly patients on polypharmacy, and patients with renal impairment all present unique pharmacologic challenges.

During pregnancy, eustachian tube dysfunction is common due to progesterone-mediated mucosal edema and increased blood volume. Intranasal saline irrigation and mechanical Valsalva maneuvers are first-line. If pharmacotherapy is needed, intranasal budesonide (pregnancy category B) is preferred over oral decongestants. Pseudoephedrine is classified as category C and has been associated with gastroschisis in first-trimester exposure data from the National Birth Defects Prevention Study [19].

Elderly patients taking multiple medications require careful review for ototoxic drug interactions. The combination of loop diuretics with aminoglycosides produces synergistic ototoxicity. Furosemide damages the blood-labyrinth barrier, increasing aminoglycoside penetration into the cochlea. A 2017 retrospective analysis in Age and Ageing (N=412) found that patients over 65 receiving both drug classes had a 3.2-fold increased risk of new-onset hearing complaints compared to either drug alone (95% CI 1.8-5.7) [20].

Monitoring protocols for patients on chronic ototoxic therapy should include audiometry every 3-6 months and patient education about early warning signs. Aural fullness that persists beyond 48 hours after drug discontinuation warrants urgent ENT referral and formal audiologic evaluation.